KRYS Earnings Prediction
The chart below shows how KRYS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KRYS sees a -1.98% change in stock price 10 days leading up to the earnings, and a +5.68% change 10 days following the report. On the earnings day itself, the stock moves by +1.24%. This data can give you a slight idea of what to expect for the next quarter's release.
KRYS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
83.84M
879.91%
19.29%
Gross Margin
92.03%
-5.50%
0.63%
Operating Margin
41.67%
113.72%
39.04%
Net Margin
32.42%
-96.56%
46.37%
EPS
0.91
-67.38%
71.70%
No Data Available
KRYS Earnings Analysis
Krystal Biotech, Inc. Common Stock Corporation (KRYS.O) Earnings Conference Call
Positive
Revenue Increase Q3: Krysal reported a net VYJUVEK revenue of $83.8 million for Q3, representing an increase of approximately $75.3 million over the third quarter of 2023.
Gross Margin Analysis: The cost of goods sold was $6.7 million for the quarter, resulting in a gross margin of 92%.
Quarterly Net Income: Net income for the quarter was $27.2 million, which represented $0.95 per basic and $0.91 per diluted share.
Milestone Net Revenue Achievement: Krysal achieved over $250 million in net revenue since the launch in August 2023, marking a significant milestone for the organization.
Strong Cash Position: The company ended the third quarter with $374 million in cash-on-hand, indicating a strong financial position.
Negative
Net Revenue Performance: Net VYJUVEK revenue for the Q came in at $83.8 million, while gross margins in GTN continued to behave as expected.
Gross Margin Analysis: Cost of goods sold was $6.7 million for the quarter or about 8% of net product revenue, resulting in a gross margin of 92%.
R&D Expense Comparison: Research and development expenses for the quarter were $13.5 million, inclusive of stock-based compensation of $2.3 million compared to $10.6 million for the prior year's third quarter, inclusive of $2.3 million of stock-based compensation.
SG&A Expense Comparison: Selling, general and administrative expenses for the quarter were $28.7 million, inclusive of stock-based compensation of $11 million compared to $23.7 million for the prior year's third quarter, inclusive of stock-based compensation of $6 million.
Litigation Settlement Expense: We recorded litigation settlement expense this quarter of $12.5 million due to our anticipation of reaching the third and final milestone payment in the PeriphaGen settlement, which is triggered at $300 million in cumulative sales payable within 30 days following the filing of our Form 10-K in which the $300 million milestone is achieved.
KRYS FAQs
How does KRYS typically perform around its earnings report dates?
Is Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KRYS Earning Call Sentiment
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
KRYS.O
-2.98%Positive
The earnings call summary indicates strong financial performance with a significant increase in VYJUVEK revenue and a solid cash position. The company is also on track with its global expansion plans. The Q&A section revealed some concerns about patient caps and compliance but overall showed positive sentiment from analysts. The management's optimistic guidance, record revenue, and high margins are likely to drive a positive stock price movement over the next two weeks.
